Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report

Extensive-stage small cell lung cancer (ES-SCLC) is characterized by an aggressive course, a high recurrence rate and fast progression. For a long time, the survival prognosis for the most patients suffering from this disease remained unfavorable. The situation changed with the appearance of chemoim...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Albina S. Zhabina, Fedor V. Moiseenko, Nikita M. Volkov, Nuriniso Kh. Abduloeva, Vladimir M. Moiseenko
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	extensive-stage small cell lung cancer chemoimmunotherapy immune checkpoint inhibitors anti-pd-l1-antibody durvalumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/879eb10584ec4d4bbd279d3d393a1085
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:879eb10584ec4d4bbd279d3d393a1085
record_format	dspace
spelling	oai:doaj.org-article:879eb10584ec4d4bbd279d3d393a10852021-11-30T16:55:01ZModern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report1815-14341815-144210.26442/18151434.2021.2.200901https://doaj.org/article/879eb10584ec4d4bbd279d3d393a10852021-08-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/70980/pdfhttps://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Extensive-stage small cell lung cancer (ES-SCLC) is characterized by an aggressive course, a high recurrence rate and fast progression. For a long time, the survival prognosis for the most patients suffering from this disease remained unfavorable. The situation changed with the appearance of chemoimmunotherapy in clinical practice. Chemotherapy based on durvalumab in comparison with the standard chemotherapy demonstrated the statistically and clinically significant increase in median overall survival in patients with previously untreated ES-SCLC in the CASPIAN international trial. This article deals with the case of the application of standard chemotherapy in combination with durvalumab as a first-line ES-SCLC therapy. The patient started receiving durvalumab therapy in June 2017 as a part of the CASPIAN international trial. In March 2021 the duration of therapy was 45 months, the patient had a complete regression of the disease.Albina S. ZhabinaFedor V. MoiseenkoNikita M. VolkovNuriniso Kh. AbduloevaVladimir M. MoiseenkoIP Habib O.N.articleextensive-stage small cell lung cancerchemoimmunotherapyimmune checkpoint inhibitorsanti-pd-l1-antibodydurvalumabNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 2, Pp 287-291 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	extensive-stage small cell lung cancer chemoimmunotherapy immune checkpoint inhibitors anti-pd-l1-antibody durvalumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	extensive-stage small cell lung cancer chemoimmunotherapy immune checkpoint inhibitors anti-pd-l1-antibody durvalumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Albina S. Zhabina Fedor V. Moiseenko Nikita M. Volkov Nuriniso Kh. Abduloeva Vladimir M. Moiseenko Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report
description	Extensive-stage small cell lung cancer (ES-SCLC) is characterized by an aggressive course, a high recurrence rate and fast progression. For a long time, the survival prognosis for the most patients suffering from this disease remained unfavorable. The situation changed with the appearance of chemoimmunotherapy in clinical practice. Chemotherapy based on durvalumab in comparison with the standard chemotherapy demonstrated the statistically and clinically significant increase in median overall survival in patients with previously untreated ES-SCLC in the CASPIAN international trial. This article deals with the case of the application of standard chemotherapy in combination with durvalumab as a first-line ES-SCLC therapy. The patient started receiving durvalumab therapy in June 2017 as a part of the CASPIAN international trial. In March 2021 the duration of therapy was 45 months, the patient had a complete regression of the disease.
format	article
author	Albina S. Zhabina Fedor V. Moiseenko Nikita M. Volkov Nuriniso Kh. Abduloeva Vladimir M. Moiseenko
author_facet	Albina S. Zhabina Fedor V. Moiseenko Nikita M. Volkov Nuriniso Kh. Abduloeva Vladimir M. Moiseenko
author_sort	Albina S. Zhabina
title	Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report
title_short	Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report
title_full	Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report
title_fullStr	Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report
title_full_unstemmed	Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report
title_sort	modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. case report
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/879eb10584ec4d4bbd279d3d393a1085
work_keys_str_mv	AT albinaszhabina modernpossibilitiesofimmunotherapyinthetreatmentofextensivestagesmallcelllungcancerexperienceofdurvalumabapplicationcasereport AT fedorvmoiseenko modernpossibilitiesofimmunotherapyinthetreatmentofextensivestagesmallcelllungcancerexperienceofdurvalumabapplicationcasereport AT nikitamvolkov modernpossibilitiesofimmunotherapyinthetreatmentofextensivestagesmallcelllungcancerexperienceofdurvalumabapplicationcasereport AT nurinisokhabduloeva modernpossibilitiesofimmunotherapyinthetreatmentofextensivestagesmallcelllungcancerexperienceofdurvalumabapplicationcasereport AT vladimirmmoiseenko modernpossibilitiesofimmunotherapyinthetreatmentofextensivestagesmallcelllungcancerexperienceofdurvalumabapplicationcasereport
_version_	1718406457391579136

Modern possibilities of immunotherapy in the treatment of extensive-stage small cell lung cancer: experience of durvalumab application. Case report

Ejemplares similares